The scene of therapeutics for Niemann-Pick Disease Type C (NPC) is a rapidly changing one, with considerable strides being made in investigation. Several potential therapeutic methods are currently experiencing clinical trials, offering optimism for individuals living with this infrequent and worsening neurodegenerative disorder. A blend of drug-d